SYRA

Syra Health is a $7.7M micro-cap healthcare-services/staffing company whose own auditors flag substantial doubt about its ability to continue as a going concern. The 10-K is explicit: recurring losses, an accumulated deficit of $9.72M, and a stated need for 'substantial additional funding' funded historically 'through the sale of our equity securities.' With only $1.61M of cash (down 32.6% YoY) and management conceding it 'may need to seek additional funds sooner than planned,' the base case for a new shareholder is dilution — the filing repeatedly warns that 'the sale of additional equity or convertible securities may dilute our stockholders' and that a dual-class structure lets Class B issuance erode Class A voting power. That risk alone makes the equity uninvestable at any price for a disciplined investor.

The genuine bright spot is the loss trajectory: net loss narrowed from -$3.76M (FY2024) to -$896K (FY2025), a 76% improvement, operating cash burn shrank to -$448K (+84.7%), and gross profit rose 50.5% to $2.49M with gross margin expanding to 34.4%. Management is clearly cutting toward breakeven. But it did so partly by starving the business — revenue actually *fell* 9.5% to $7.23M, total assets shrank 24.6%, and R&D collapsed 88.4% to $67.8K, undercutting the 'digital health / Syrenity / SyraBot' growth narrative the MD&A leans on. This is contraction dressed as discipline, not durable, profitable growth.